TWi Pharmaceuticals, Inc.
Allison Liao is a seasoned professional with extensive experience in pharmaceutical and financial sectors. Currently serving as Senior Manager at TWi Pharmaceuticals, Inc. since February 2022, Allison has also held positions such as Fund Operation Manager at Taiwania Capital from November 2018 to January 2022, and Associate Manager in Post Management at KHL Capital in 2017. Prior to these roles, Allison worked as an Accounting Manager at TWi Pharmaceuticals from 2014 to 2017, and as an Associate Manager in Audit at KPMG from 2011 to 2014. Education was completed at National Taiwan University.
This person is not in any teams
TWi Pharmaceuticals, Inc.
focusing on the development and commercialization of "High Barrier to Entry" generic drugs. TWi focuses primarily on the development of Paragraph IV and high technical barrier generic drugs requiring strong science and technical know-how, as well as under-serviced mature molecules to meet market needs. For more information about TWi Corporate and "High Barrier to Entry" generics, please click here to visit www.twipharma.com. Our goals are to expand our market presence in the United States as a strong industry partner, and to continue to identify, acquire, develop, license and launch technically challenging or mature molecule generic drugs.